Suggested remit - To appraise the clinical and cost effectiveness of ofatumumab within its marketing authorisation for treating relapsing forms of multiple sclerosis.
Status Proposed
Process STA 2018
ID number 1677

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
19 November 2019 - 17 December 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance